Brett Sandercock - Jul 22, 2022 Form 4 Insider Report for RESMED INC (RMD)

Role
Chief Financial Officer
Signature
Brett Sandercock, Chief Financial Officer
Stock symbol
RMD
Transactions as of
Jul 22, 2022
Transactions value $
-$1,329,300
Form type
4
Date filed
7/26/2022, 11:59 AM
Previous filing
Apr 12, 2022
Next filing
Aug 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $144K +2.5K +2.35% $57.76 109K Jul 22, 2022 Direct F1
transaction RMD ResMed Common Stock Options Exercise $144K +2.5K +2.3% $57.76 111K Jul 22, 2022 Direct F1
transaction RMD ResMed Common Stock Options Exercise $144K +2.5K +2.24% $57.76 114K Jul 22, 2022 Direct F1
transaction RMD ResMed Common Stock Sale -$1.76M -7.5K -6.58% $235.00 106K Jul 22, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -2.5K -25% $0.00 7.5K Jul 22, 2022 ResMed Common Stock 2.5K $57.76 Direct F3
transaction RMD ResMed Common Stock Options Options Exercise $0 -2.5K -33.33% $0.00 5K Jul 22, 2022 ResMed Common Stock 2.5K $57.76 Direct F3
transaction RMD ResMed Common Stock Options Options Exercise $0 -2.5K -50% $0.00 2.5K Jul 22, 2022 ResMed Common Stock 2.5K $57.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan.
F2 Includes 71.359 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan.
F3 Represents date options first became exercisable. Options vest 1/3 per year.